We report here the results of the diagnostic performances of Vitros Syphilis TPA (a chemiluminescence treponemal assay) compared with those of two treponemal enzyme immunoassays and of traditional versus reverse syphilis algorithms. Ease of use, automation, and high throughput make the Vitros Syphilis TPA assay a good choice for syphilis screening in high-volume laboratories.
S
yphilis is a global health problem, with 10.6 million adult cases reported in 2008 (1) . Classical syphilis screening uses nontreponemal (rapid plasma reagin [RPR] or Venereal Disease Research Laboratory [VDRL]) tests. Reactive specimens are confirmed using treponemal assays (Treponema pallidum hemagglutination assay [TPHA] ) or fluorescent treponemal antibody absorption (FTAAbs) tests. Most high-volume laboratories have adopted "reversealgorithm" syphilis screening to improve efficiency and lower costs (2) (3) (4) (5) . In order to guide our adoption of these assays, we evaluated the performance of the Vitros Syphilis TPA chemiluminescence immunoassay (CLIA) for routine screening compared to those of two other treponemal enzyme immunoassays, the Enzygnost Syphilis IgG ϩ IgM and the Bioelisa Syphilis 3.0. We prospectively analyzed (i) 317 serum samples from the Laboratori Clínic de l'Hospitalet using the Vitros Syphilis TPA and Bioelisa assays and (ii) 300 serum samples from the Microbiology Department of the Hospital Universitari Vall d'Hebró using the Vitros Syphilis TPA and Enzygnost assays. Specimens that tested negative by the CLIA and/or enzyme immunoassay (EIA) were considered definitively negative; reactive specimens were tested by the RPR and TPHA tests. Discordant CLIA/EIA and TPHA results were resolved using an FTA-Abs test. Specimens with an absorbance of Ͼ3.00 according to the Bioelisa assay were confirmed by the INNO-LIA Syphilis assay (Fujirebio Iberia S.L.U., Barcelona, Spain). The overall efficacy of reverse syphilis screening was evaluated by comparing traditional and reverse-sequence algorithms in 792 prospective serum samples using the RPR and Vitros Syphilis TPA assays, respectively. Of these, 402 were analyzed in the Hospital Universitari Germans Trias i Pujol Microbiology Department and 390 in the Hospital Universitari Santa Creu i Sant Pau Microbiology Department. Specimens with discordant RPR and Vitros Syphilis TPA results were tested using TPHAs, and discordant Vitros Syphilis TPA and/or RPR and TPHA results were tested using FTA-Abs assays.
The Hospital Universitari Germans Trias i Pujol Ethics Committee approved the study. The Vitros Syphilis TPA assay (Ortho Clinical Diagnostics, Inc., High Wycombe, United Kingdom) is a fully automated chemiluminescent immunoassay (double-antigen sandwich) for the qualitative detection of IgG and IgM and was performed on the Vitros 3600 instrument. Antibodies react with biotinylated recombinant Treponema pallidum antigens (TP15, TP17, TP47) and horseradish peroxidase (HRP)-labeled Treponema pallidum antigen conjugate (recombinant TP15, TP17, and TP47 antigens). The antibody-antigen complex is captured by streptavidin-coated wells, and unbound materials are washed off. A luminogenic substrate reagent (a luminol derivate and a peracid salt) and electron transfer agent (increasing light production and duration) are added. HRP in the conjugate catalyzes luminol oxidation, producing light, which is read by the system. Bound HRP conjugates are directly proportional to anti-TP antibody concentrations in sera. Vitros results are expressed as a test sample signal/signal at cutoff (S/CO) ratio. Ratios of Ͻ0.80, between 0.80 and 1.20, and Ն1.20 correspond to negative, indeterminate, and positive results, respectively.
The RPR, TPHA, and Bioelisa (all from Biokit SA, Barcelona, Spain), Enzygnost (Siemens Healthcare Diagnostics, Marburg, Germany), and INNO-LIA (Fujirebio Iberia S.L.U., Barcelona, Spain) assays were performed and interpreted according to the manufacturers' instructions (6). The TPHA or FTA test was used as the gold standard for calculations of sensitivities, specificities, and positive (PPV) and negative predictive values (NPV). Correlations between the Vitros Syphilis TPA and Bioelisa or Enzygnost assays were assessed through kappa coefficients (7). There was almost perfect agreement between the Vitros Syphilis TPA and Bioelisa assays ( ϭ 0.83; 95% confidence interval [CI], 0.72 to 0.94). Of 317 specimens, 283 were negative and 25 were posi- tive by both tests (24 of which were confirmed by TPHA). One patient tested positive by the Bioelisa assay (absorbance, 5.62) and the CLIA but had negative TPHA, FTA, and RPR results. The INNO-LIA assay was indeterminate (TpN17 band), and the patient had been treated for syphilitic chancre. He subsequently tested positive by Bioelisa, and although his test was never positive according to the TPHA, he was finally classified as positive on the basis of clinical picture. The remaining nine specimens had discordant results. Two were weakly positive by the Vitros Syphilis TPA assay (S/CO ratios, 1.92 and 2.32, respectively) and negative by the Bioelisa assay. Each of the two was negative according to the RPR, TPHA, and FTA tests. The Vitros Syphilis TPA results were considered false positive. The remaining seven specimens were Vitros Syphilis TPA negative and weakly positive by the Bioelisa assay (absorbance, 1.02 to 2.39). All were RPR, TPHA, and FTA negative and also considered false positive. The sensitivities, specificities, PPV, and NPV are shown in Table 1 . Agreement between the Vitros Syphilis TPA and Enzygnost assays was almost perfect ( ϭ 0.96; 95% CI, 0.91 to 1.00). Both assays classified 283 specimens as negative and 16 specimens as positive (confirmed by TPHA). The remaining specimen was Vitros Syphilis TPA positive (S/CO ratio, 52.1) and Enzygnost negative. It was RPR positive (titer of 1/4) and TPHA and FTA negative. The patient was a 66-year-old woman from Equatorial Guinea seen in an immigrant screening clinic. The RPR test was considered to be nonspecific, as TPHA and FTA were negative. This result was difficult to interpret and was finally classified as a false-positive Vitros Syphilis TPA. Sensitivities, specificities, PPVs, and NPVs are shown in Table 2 . The specificity of the Vitros Syphilis TPA was high and similar to those obtained with the two other enzyme immunoassays; these findings are consistent with those of other studies (8, 9) . Of 792 serum samples used to compare traditional and reverse syphilis screening, 723 were negative by the Vitros Syphilis TPA and RPR assays, and 38 were positive by these two assays and confirmed by TPHA. The remaining 31 serum samples were discordant (Table 3) . Of these, three were RPR positive (titers of 1/2 and 1/8) and Vitros Syphilis TPA and TPHA negative. These specimens were from two HIV patients and one patient with systemic lupus erythematosus, recognized causes of false reactions in nontreponemal tests (10) . Seventeen specimens were RPR negative but Vitros Syphilis TPA and TPHA positive; all were from patients with previous or treated syphilis. Nine specimens were Vitros Syphilis TPA positive and RPR and TPHA neg- 
